Amarin Corporation plc (NASDAQ:AMRN) SVB Securities Global Biopharma Conference February 14, 2023 10:40 AM ET Company Participants Karim Mikhail - President & CEO Tom Reilly - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Securities Roanna Ruiz Great. Welcome back, everyone. I'm Roanna Ruiz, Senior Biotech Analyst here at SVB Securities, and it's my pleasure to introduce members of the Amarin management team, specifically, Karim Mikhail, President and CEO and Tom Reilly, CFO. So wel ...

SVB Securities Global Biopharma Conference Karim Mikhail President & CEO February 14, 2023 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements which are made pursuant to U.S. federal securities law, including beliefs about Amarin's key achievements in 2022 and the potential impact and outlook for achievements in 2023 and beyond; Amarin's 2023 financial outlook and cash position; strategies to ensure profit maximization; Amarin's strategic direction and actions manag ...

41st Annual J.P. Morgan Healthcare Conference Karim Mikhail President & CEO January 23 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in na ...

Amarin Corporation plc (NASDAQ:AMRN) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 8:15 PM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer [Call Starts Abruptly] -- in Europe. And the Board took upon itself to refresh itself also. So, they have initiated a process, in October, of 2021. And for now, we basically have 75% of new board members. So, you see on the list here all the new board members who were added to the list wh ...

Amarin Corporation plc (NASDAQ:AMRN) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 9:40 AM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Well, we'll get stared. Hey, it's Michael Yee here, senior biotechnology analyst at Jefferies. Very happy to have the team from Amarin. Up here with us to give a brief presentation, we have the CEO, Karim Mikhail ...

Amarin Corporation plc (NASDAQ:AMRN) Q3 2022 Results Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Georgi Yordanov - Cowen and Company Roanna Ruiz - SVB Leerink Carvey Leung - Cantor Fitzgerald Daniel Wolle - J.P. Morgan Paul Choi - Goldman Sachs Operator W ...

Amarin Corporation Plc (NASDAQ:AMRN) H.C. Wainwright Global Investment Conference September 12, 2022 9:00 AM ET Company Participants Karim Mikhail - President, CEO & Director Thomas Reilly - CFO & SVP Conference Call Participants Andrew Fein - H.C. Wainwright & Co. Andrew Fein Hello, everyone. I'm Andrew Fein, one of the biotechnology analysts at H.C. Wainwright. Thank you for coming. Glad to be back in person. So the next company presenting will be Amarin, and presenting for the company will be its Presid ...

Amarin Corporation plc (NASDAQ:AMRN) Q2 2022 Results Conference Call August 3, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - SVP, IR and Corporate Affairs Karim Mikhail - President and CEO Dr. Steve Ketchum - President, R&D and Chief Scientific Officer Tom Reilly - CFO Conference Call Participants Louise Chen - Cantor Roanna Ruiz - SVB Securities Daniel Wolle - JP Morgan Operator Welcome to Amarin Corporation’s Conference Call to discuss its Second Quarter 2022 Financial Results and Operational Up ...